PT2358361T - Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina - Google Patents
Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidinaInfo
- Publication number
- PT2358361T PT2358361T PT97528251T PT09752825T PT2358361T PT 2358361 T PT2358361 T PT 2358361T PT 97528251 T PT97528251 T PT 97528251T PT 09752825 T PT09752825 T PT 09752825T PT 2358361 T PT2358361 T PT 2358361T
- Authority
- PT
- Portugal
- Prior art keywords
- derivate
- pyrrolidine
- oxo
- release formulations
- prolonged release
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08105817 | 2008-11-18 | ||
| EP09100311 | 2009-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2358361T true PT2358361T (pt) | 2016-11-18 |
Family
ID=41395028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97528251T PT2358361T (pt) | 2008-11-18 | 2009-11-17 | Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8460712B2 (enExample) |
| EP (1) | EP2358361B1 (enExample) |
| JP (2) | JP5954889B2 (enExample) |
| KR (2) | KR101788804B1 (enExample) |
| CN (2) | CN104083341A (enExample) |
| AU (1) | AU2009317279B2 (enExample) |
| BR (1) | BRPI0921301A2 (enExample) |
| CA (1) | CA2741038C (enExample) |
| DK (1) | DK2358361T3 (enExample) |
| EA (1) | EA019583B1 (enExample) |
| ES (1) | ES2602606T3 (enExample) |
| HK (1) | HK1198288A1 (enExample) |
| HU (1) | HUE030963T2 (enExample) |
| IL (1) | IL212271A (enExample) |
| MX (1) | MX356281B (enExample) |
| PL (1) | PL2358361T3 (enExample) |
| PT (1) | PT2358361T (enExample) |
| WO (1) | WO2010057869A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2358360T3 (en) * | 2008-11-18 | 2016-12-12 | Ucb Biopharma Sprl | EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| WO2017195144A1 (en) * | 2016-05-12 | 2017-11-16 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| CA3216586A1 (en) * | 2021-05-11 | 2022-11-17 | Caroline Roussel-Maupetit | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
| TR2023017170A1 (tr) * | 2023-12-13 | 2025-06-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bri̇varasetam i̇çeren bi̇r saşe formülasyonu |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| NZ556630A (en) * | 2005-01-27 | 2010-12-24 | Alembic Ltd | Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| WO2006088864A1 (en) * | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
| US8431156B2 (en) * | 2005-02-22 | 2013-04-30 | Sun Pharma Advanced Research Company Ltd. | Pharmaceutical composition |
| JP2008534530A (ja) * | 2005-03-29 | 2008-08-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形 |
| FR2897267A1 (fr) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| BRPI0712325A2 (pt) * | 2006-06-08 | 2012-01-10 | Ucb Pharma Sa | processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal |
| ES2953390T3 (es) | 2006-08-31 | 2023-11-10 | Adare Pharmaceuticals Inc | Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| US9555006B2 (en) * | 2007-09-21 | 2017-01-31 | Evonik Roehm Gmbh | PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| BRPI0908421C1 (pt) | 2008-03-03 | 2021-05-25 | Ucb Biopharma Sprl | solução estável de um composto farmacêutico |
-
2009
- 2009-11-17 DK DK09752825.1T patent/DK2358361T3/en active
- 2009-11-17 EA EA201100753A patent/EA019583B1/ru unknown
- 2009-11-17 HU HUE09752825A patent/HUE030963T2/en unknown
- 2009-11-17 PL PL09752825T patent/PL2358361T3/pl unknown
- 2009-11-17 ES ES09752825.1T patent/ES2602606T3/es active Active
- 2009-11-17 US US13/128,950 patent/US8460712B2/en active Active
- 2009-11-17 PT PT97528251T patent/PT2358361T/pt unknown
- 2009-11-17 JP JP2011543762A patent/JP5954889B2/ja active Active
- 2009-11-17 BR BRPI0921301A patent/BRPI0921301A2/pt not_active IP Right Cessation
- 2009-11-17 WO PCT/EP2009/065270 patent/WO2010057869A1/en not_active Ceased
- 2009-11-17 CN CN201410370727.9A patent/CN104083341A/zh active Pending
- 2009-11-17 CA CA2741038A patent/CA2741038C/en active Active
- 2009-11-17 CN CN2009801455887A patent/CN102215828A/zh active Pending
- 2009-11-17 EP EP09752825.1A patent/EP2358361B1/en active Active
- 2009-11-17 KR KR1020177000418A patent/KR101788804B1/ko active Active
- 2009-11-17 KR KR1020117014019A patent/KR20110089184A/ko not_active Ceased
- 2009-11-17 AU AU2009317279A patent/AU2009317279B2/en active Active
- 2009-11-17 MX MX2011004572A patent/MX356281B/es active IP Right Grant
-
2011
- 2011-04-12 IL IL212271A patent/IL212271A/en active IP Right Grant
-
2014
- 2014-11-21 HK HK14111805.6A patent/HK1198288A1/xx unknown
-
2015
- 2015-03-31 JP JP2015071166A patent/JP2015143256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102215828A (zh) | 2011-10-12 |
| EA019583B1 (ru) | 2014-04-30 |
| IL212271A (en) | 2016-10-31 |
| EP2358361A1 (en) | 2011-08-24 |
| WO2010057869A1 (en) | 2010-05-27 |
| HUE030963T2 (en) | 2017-06-28 |
| IL212271A0 (en) | 2011-06-30 |
| MX2011004572A (es) | 2011-06-17 |
| BRPI0921301A2 (pt) | 2015-12-29 |
| ES2602606T3 (es) | 2017-02-21 |
| KR101788804B1 (ko) | 2017-10-20 |
| EP2358361B1 (en) | 2016-09-14 |
| US8460712B2 (en) | 2013-06-11 |
| EA201100753A1 (ru) | 2012-01-30 |
| AU2009317279A1 (en) | 2010-05-27 |
| CA2741038A1 (en) | 2010-05-27 |
| KR20170007528A (ko) | 2017-01-18 |
| JP2012509356A (ja) | 2012-04-19 |
| CN104083341A (zh) | 2014-10-08 |
| PL2358361T3 (pl) | 2017-02-28 |
| DK2358361T3 (en) | 2016-12-12 |
| JP5954889B2 (ja) | 2016-07-20 |
| US20110274762A1 (en) | 2011-11-10 |
| MX356281B (es) | 2018-05-22 |
| HK1198288A1 (en) | 2015-03-27 |
| KR20110089184A (ko) | 2011-08-04 |
| AU2009317279B2 (en) | 2013-10-24 |
| CA2741038C (en) | 2015-01-13 |
| JP2015143256A (ja) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212447A0 (en) | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative | |
| GB0815435D0 (en) | Formulations | |
| GB2459691B (en) | Formulations | |
| SG10201703039SA (en) | Sustained release formulations using non-aqueous carriers | |
| GB0823269D0 (en) | Formulations | |
| GB0817938D0 (en) | Cosmetic formulations | |
| IL208601A0 (en) | Dried formulations | |
| GB0821789D0 (en) | Formulations | |
| EP2297218A4 (en) | AMPHIPHILIC SEQUENCED COPOLYMER FORMULATIONS | |
| EP2307021A4 (en) | FORMULATIONS | |
| IL213559A0 (en) | Oral formulations | |
| IL212271A0 (en) | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate | |
| EP2296709A4 (en) | NIACIN FORMULATIONS WITH MODIFIED RELEASE | |
| GB0806978D0 (en) | Novel formulations | |
| GB0705179D0 (en) | Formulations | |
| GB0921378D0 (en) | Formulations | |
| GB0916030D0 (en) | Formulations | |
| GB0822171D0 (en) | Temisartan formulations | |
| GB0811447D0 (en) | Formulations | |
| GB0823493D0 (en) | Formulations | |
| GB0817079D0 (en) | Formulations | |
| GB0823486D0 (en) | Formulations | |
| GB0916106D0 (en) | Formulations | |
| GB0816876D0 (en) | Formulations | |
| GB0807906D0 (en) | Formulations |